The CDC's Leadership Crisis Is Far From Over
Robert F. Kennedy Jr. sat before the House Ways and Means Committee on Wednesday and did something he's rarely done in two decades of public advocacy: he kept his mouth shut about vaccines. When pressed on his long-held claims about vaccine dangers, the Health and Human Services secretary largely deflected. When asked whether the unvaccinated Texas girl who died of measles last year could have been saved by the MMR shot, his answer was measured almost to the point of being unrecognizable: "It's possible, certainly."
That restraint isn't a change of heart. It's a political calculation — and understanding the difference matters enormously for anyone trying to gauge where American public health policy is headed.
Why Kennedy Went Quiet
The White House has reportedly instructed Kennedy to dial back his vaccine commentary, concerned that his decades-long crusade against immunization could become an electoral liability heading into the midterms. The pivot has been swift and conspicuous. In place of vaccine skepticism, Kennedy is now championing revised dietary guidelines — a new inverted food pyramid — and the return of whole milk to school cafeterias. His new podcast launched this week with celebrity chef Robert Irvine, who Kennedy credits with revamping military meals. The episode, notably, was filmed in front of shelves lined with Kennedy's own books and family photographs.
The optics of the silence shouldn't be mistaken for substance. Kennedy has already used his time as HHS secretary to reshape the institutional machinery that governs vaccine policy. Last summer, he filled the CDC's vaccine advisory board — the Advisory Committee on Immunization Practices (ACIP) — with ideological allies. A federal judge subsequently blocked changes that board made to the childhood vaccine schedule and declared most of its members illegitimate. Kennedy's response last week was to quietly amend the board's governing charter, inserting language directing it to identify "gaps in vaccine safety research including adverse effects following vaccination." That framing — bureaucratic in tone, loaded in implication — is precisely the kind of incremental policy shift that outlasts any news cycle.
The CDC's Vacancy Problem Is Bigger Than a Personnel Chart
The nomination of Erica Schwartz as CDC director is the most concrete signal yet that the Trump administration recognizes the agency's leadership crisis has become untenable. The CDC has had a confirmed director for just 29 days since Kennedy took office. Its current acting head, Jay Bhattacharya — who simultaneously serves as director of the National Institutes of Health — holds the position in a technical limbo: the administration missed its own deadline to formally nominate a new director, stripping him of the acting title even as he apparently continues to run the agency.
Bhattacharya's stewardship has drawn its own scrutiny. This month, he reportedly delayed publication of a CDC study demonstrating that COVID vaccines reduce hospitalization risk. An HHS spokesperson told The New York Times that he wanted to ensure the paper used "the most appropriate methodology" — a response that, to scientists who know how peer review works, reads as institutional interference dressed in procedural language.
Schwartz arrives with credentials that are hard to dismiss. A retired rear admiral in the U.S. Public Health Service, she holds a medical degree from Brown University and a law degree from the University of Maryland. She served during the COVID pandemic in the first Trump administration. Several current and former CDC employees who spoke to reporters welcomed her potential selection — itself a telling detail, given how demoralized the agency's workforce has become following a wave of high-profile resignations.
What "Qualified" Actually Means at the CDC Right Now
Schwartz's qualifications are real. But the more revealing question isn't whether she's capable — it's whether she'll be allowed to act on that capability.
The CDC's last permanent director, Susan Monarez, testified that she was dismissed for refusing to implement Kennedy's agenda and for protecting certain public-health experts from removal. Kennedy has offered a different characterization — he said she was fired for denying that she was trustworthy — but the underlying dynamic is clear: the secretary views the agency's scientific establishment with suspicion, and has demonstrated he's willing to act on that suspicion.
Daniel Jernigan, who led the CDC's National Center for Emerging and Zoonotic Infectious Diseases before resigning in protest over Monarez's firing, offered a blunt assessment: for any incoming CDC director, he said, accommodating Kennedy's anti-vaccine views is "likely a necessary job skill." That's not the kind of job description that typically appears in public-health leadership discussions.
The question hanging over Schwartz's potential tenure isn't competence — it's whether the role she's been offered has enough institutional independence to be worth taking. Two months ago, Chris Klomp, the head of Medicare, was repositioned as the department's chief counselor, reportedly to keep Kennedy in check. The administration is stacking advisers around Kennedy while simultaneously pressuring him to moderate his public statements. That's a delicate internal balance, and one that historically doesn't hold for long.
Filling Roles, But Not Restoring Trust
Alongside Schwartz's nomination, the administration announced other significant appointments. Jennifer Shuford, an infectious-disease specialist who served as Texas's health commissioner during last year's measles outbreak and explicitly emphasized the importance of vaccination, will become the CDC's deputy director and chief medical officer. Sara Brenner, a physician currently serving as principal deputy commissioner of the FDA, will move to HHS as a senior counselor to Kennedy.
These are not random selections. Shuford, in particular, has a track record that includes publicly defending measles vaccination during a genuine public-health emergency — a position that, in the current environment, required some political courage. Her appointment could represent a quiet acknowledgment within the administration that the Texas outbreak was a preventable tragedy with political consequences.
But personnel changes, however credentialed, don't automatically repair the institutional damage of the past year. The CDC has lost experienced scientists, seen internal morale collapse, and watched its advisory structures be legally challenged and administratively restructured. The incoming team will inherit an agency that has spent over a year being treated by its own department secretary as an adversary.
Reading the Signals
Kennedy before Congress this week was a noticeably diminished figure — careful, hedged, stripped of the rhetorical confidence that built his public following. The White House's calculation is straightforward: an HHS secretary publicly questioning childhood vaccines is a political problem. A quieter Kennedy, focused on food policy and military nutrition, is easier to manage.
What's harder to manage — and what the Schwartz nomination and the revised ACIP charter both illustrate — is that the institutional changes Kennedy has already made don't require him to keep talking. The charter language directing the vaccine advisory board to investigate "adverse effects following vaccination" will shape research priorities and public communications long after Kennedy's media appearances fade. The appointments he made to that board last summer set in motion a legal battle that has already delayed vaccine schedule decisions and seeded public uncertainty.
The administration may have tamed Kennedy's public voice. It has not undone what that voice already set in motion — and the new CDC director, whoever ultimately holds the role, will have to reckon with that inheritance from day one.
